Compare BKR & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKR | NTRA |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | United States |
| Employees | 64000 | N/A |
| Industry | Metal Fabrications | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.0B | 56.7B |
| IPO Year | 2017 | 2015 |
| Metric | BKR | NTRA |
|---|---|---|
| Price | $55.56 | $406.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 23 |
| Target Price | $71.17 | ★ $403.89 |
| AVG Volume (30 Days) | ★ 5.6M | 1.5M |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | ★ 56.02 | 0.65 |
| EPS | ★ 2.98 | N/A |
| Revenue | ★ $27,733,000,000.00 | $210,939,000.00 |
| Revenue This Year | $6.52 | $26.19 |
| Revenue Next Year | $10.31 | $20.84 |
| P/E Ratio | $18.52 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $44.26 | $181.00 |
| 52 Week High | $70.41 | $437.41 |
| Indicator | BKR | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 42.33 | 58.90 |
| Support Level | $53.72 | $380.39 |
| Resistance Level | $58.79 | $437.41 |
| Average True Range (ATR) | 1.47 | 17.98 |
| MACD | 0.04 | -3.92 |
| Stochastic Oscillator | 38.63 | 39.00 |
Following a 2022 reorganization, Baker Hughes operates in two segments: oilfield services and equipment, and industrial and energy technology. The firm's oilfield services and equipment segment is one of the Big Three oilfield-services players, along with SLB and Halliburton, and mostly supplies to hydrocarbon developers and producers, including national oil companies, major integrated firms, and independents. Markets outside of North America buy roughly three-fourths of the segment's offerings. Baker Hughes' industrial and energy technology segment manufactures and sells turbines, compressors, pumps, valves, and related testing and monitoring services for various energy and industrial applications.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.